The WADA (West Africa Data Base on Antiretroviral Therapy) Collaboration is a unique collaboration among cohorts in West Africa with a mission to conduct hypothesis-driven epidemiological research on the prognosis and outcomes of HIV-1 and HIV-2-infected people, including adults, pregnant mothers, and children in care and generally on treatment, as well as HIV-exposed children. Our five-year research plan will focus on scientific questions requiring a large sample size of patients that the contributing cohorts cannot answer individually and which do not overlap with existing projects. During the five years of the next leDEA round, the overall aims of WADA are:1)to measure the effectiveness of combination antiretroviral treatment (ART) in West Africa in the long term, and to assess factors that influence outcomes; 2) to increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children; 3) to document the morbidity burden in HIV- infected individuals in care in HIV programs throughout West Africa. To date, the pooled database assembled by the WADA Collaboration in the current leDEA cycle includes 33,815 HIV-infected adults and 3,533 HIV- infected children who initiated ART in 26 clinics. The next round will involve 27 HIV centers (adults: 16, pediatrics: 11) in nine countries (Benin, Burkina Faso, Cote d'lvoire, Ghana, Guinea Bissau, Mali, Nigeria, Senegal, Togo). Among them, two new countries (Guinea Bissau and Togo) and five HIV clinics (three adult clinics and two pediatric clinics) are new collaborating centers. WADA is jointly coordinated by the WADA Coordinating Center at the Bordeaux School of Public Health (ISPED) in Bordeaux University, France (Prof. Francois Dabis) with a WADA Regional Office hosted by PAC-CI, a research-oriented non-governmental organization situated in Abidjan, Cote d'lvoire. This research team has a long-lasting experience in observational HIV research including large-scale prospective cohorts in West Africa and will continue and expand the ongoing leDEA-funded cycle. Data will be collected from affiliated cohorts every year according to standardized procedures. Capacity building in participating centers will include funding for local human resources, training on data quality, on-site technical support and annual meetings to reinforce the technical and scientific network. The priority research agenda will address the following topics: retention in care, natural history of HIV-2 and HIV-1/HIV-2 infections, cancer, malaria, hepatitis B, pregnancy outcomes, pharmacovigilance, adolescent and pediatric access and efficiency of care.
Clinical and operational research assessing the efficiency of HIV care programs require reliable information systems and capacity building for sustaining this activity in the long term. The WADA collaboration has already implemented a network of HIV care centers and will reinforce its commitment to study morbidities including cancer, malaria, hepatitis B and adverse drug reactions. The HIV-2 cohort will be strengthened with the organization of a blood bank Children will be enrolled from the time of HIV exposure.
|Schomaker, Michael; Heumann, Christian (2018) Bootstrap inference when using multiple imputation. Stat Med 37:2252-2266|
|Jaquet, Antoine; Tchounga, Boris; Tanon, Aristophane et al. (2018) Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer 143:869-877|
|IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903|
|Wools-Kaloustian, Kara; Marete, Irene; Ayaya, Samuel et al. (2018) Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. J Acquir Immune Defic Syndr 78:221-230|
|Arrivé, Elise; Ayaya, Samuel; Davies, Mary-Ann et al. (2018) Models of support for disclosure of HIV status to HIV-infected children and adolescents in resource-limited settings. J Int AIDS Soc 21:e25157|
|Jaquet, Antoine; Wandeler, Gilles; Nouaman, Marcellin et al. (2017) Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study. J Int AIDS Soc 19:21424|
|Jaquet, Antoine; Nouaman, Marcellin; Tine, Judicaël et al. (2017) Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. Liver Int 37:1116-1121|
|Brennan, Alana T; Davies, Mary-Ann; Bor, Jacob et al. (2017) Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa? AIDS 31:147-157|
|Coffie, Patrick A; Egger, Matthias; Vinikoor, Michael J et al. (2017) Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. BMC Infect Dis 17:706|
|Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40|
Showing the most recent 10 out of 106 publications